Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06504589 · ClinicalTrials.gov registry record
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
A clinical trial of Cystic Fibrosis, sponsored by Nicole Hamblett.
- Recruiting
- Registry status
- 400
- Enrollment target
- 20
- Study locations
NCT06504589 is a study of Cystic Fibrosis that is actively recruiting participants, run by Nicole Hamblett. The registered enrollment target is 400 participants, above the 177-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (126% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06504589, a study of Cystic Fibrosis, is actively recruiting participants, sponsored by Nicole Hamblett.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study.
Conditions Studied
Study Locations (20)
California
- University of California San Diego - La Jolla
- Childrens Hospital Los Angeles - Los Angeles
- Stanford University Medical Center - Palo Alto
- University of California, San Francisco - Adult Center - San Francisco
- University of California, San Francisco - Peds Center - San Francisco
Florida
- University of Florida - Gainesville
- University of Miami - Miami
- Central Florida Pulmonary Group - Orlando
- Tampa General Hospital - Tampa
Arizona
- Phoenix Children's Hospital - Phoenix
- Tucson Cystic Fibrosis Center - Tucson
Colorado
- Children's Hospital Colorado - Aurora
- National Jewish Health - Denver
Georgia
- Children's Healthcare of Atlanta and Emory University - Atlanta
- Augusta University - Augusta
Alabama
- The Children's Hospital Alabama, University of Alabama at Birmingham - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Idaho
- Saint Luke's Cystic Fibrosis Center of Idaho - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2029-08-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06504589
The ClinicalTrials.gov registry entry for NCT06504589 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 177-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (126% higher). The listed sponsor is Nicole Hamblett, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT06504589 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06504589 about?
NCT06504589 is a clinical study titled "A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators". The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inf...
What is the current status of trial NCT06504589?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-09-18. Estimated completion is 2029-08-14.
What conditions does trial NCT06504589 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
Who is sponsoring clinical trial NCT06504589?
This trial is sponsored by Nicole Hamblett, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06504589 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
-
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.